



**Figure S7.** Viability of human NC cell line 690100 after dual combination treatment with T-VEC and small molecule inhibitors (SMIs): 690100 cells were infected with T-VEC at a multiplicity of infection (MOI) of 0.001 and treated with the SMIs vorinostat (1  $\mu$ M) (A), panobinostat (1 nM) (B), fimepinostat (0.5 nM) (C), GNE-781 (10 nM) (D), palbociclib (3  $\mu$ M) (E) in dual combination or alone, or remained untreated (MOCK). The remaining NC tumor cells were determined at 72 h post-infection (hpi) by SRB viability assays. The mean  $\pm$  SD of at least two independent experiments performed in triplicates is shown. Reported significances refer to dual combination compared to the respective monotherapy with the lowest remaining cell viability. \*  $p < 0.05$ ; \*\*  $p < 0.01$ , \*\*\*\*  $p < 0.0001$ , n.s. not significant.